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Abstract
Background
Accurately predicting the probability of a live birth after in vitro fertilisation (IVF) is important
for patients, healthcare providers and policy makers. Two prediction models (Templeton
and IVFpredict) have been previously developed from UK data and are widely used interna-
tionally. The more recent of these, IVFpredict, was shown to have greater predictive power
in the development dataset. The aim of this study was external validation of the two models
and comparison of their predictive ability.
Methods and Findings
130,960 IVF cycles undertaken in the UK in 2008–2010 were used to validate and compare
the Templeton and IVFpredict models. Discriminatory power was calculated using the area
under the receiver-operator curve and calibration assessed using a calibration plot and
Hosmer-Lemeshow statistic. The scaled modified Brier score, with measures of reliability
and resolution, were calculated to assess overall accuracy. Both models were compared
after updating for current live birth rates to ensure that the average observed and predicted
live birth rates were equal. The discriminative power of both methods was comparable: the
area under the receiver-operator curve was 0.628 (95% confidence interval (CI): 0.625–
0.631) for IVFpredict and 0.616 (95% CI: 0.613–0.620) for the Templeton model. IVFpredict
had markedly better calibration and higher diagnostic accuracy, with calibration plot inter-
cept of 0.040 (95% CI: 0.017–0.063) and slope of 0.932 (95% CI: 0.839–1.025) compared
with 0.080 (95% CI: 0.044–0.117) and 1.419 (95% CI: 1.149–1.690) for the Templeton
model. Both models underestimated the live birth rate, but this was particularly marked in
the Templeton model. Updating the models to reflect improvements in live birth rates since
the models were developed enhanced their performance, but IVFpredict remained superior.
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Conclusion
External validation in a large population cohort confirms IVFpredict has superior discrimina-
tion and calibration for informing patients, clinicians and healthcare policy makers of the
probability of live birth following IVF.
Introduction
For a patient or couple considering in-vitro fertilisation (IVF) the most important prognosis is
that of a live birth, and for the clinician advising them it is important to be able to provide an
accurate assessment of that prognosis [1]. For policy makers, precise estimates of prognosis are
essential to model the population burden of infertility and treatment, and to inform cost-effec-
tive healthcare provision [2,3]. As clinicians’ assessment of prognosis are widely varied [4,5],
several prediction models have been developed to give the prognosis of live birth based on pa-
tient and couple characteristics and measurements, in order to better inform patients and clini-
cians [6–14]. Many of these include measurements that would not be available prior to
commencing the first cycle of IVF, and would hence have limited ability to inform decisions,
and/or have not been externally validated.
Two prediction models have been developed using data from the UK [7,12], where there is a
statutory legal requirement to maintain a national record of every initiated IVF cycle and its
outcome. The first of these, the Templeton model [7], has been widely used [1], externally vali-
dated [12,15–18], and recommended as the best model in systematic reviews [1,15]. However,
it was developed using data from couples who received IVF two decades ago, when successful
live birth rates were considerably lower than currently, and before the introduction of intra-cy-
toplasmic sperm injection (ICSI), which has transformed the treatment of male infertility [19].
Recently, we developed IVFpredict in the largest IVF prediction study to date (144,018 cycles)
and added prognostic characteristics, including ICSI, to those used in the Templeton model
[12]. We demonstrated that IVFpredict had superior discrimination and calibration to the
Templeton model [12], and this model is increasingly used internationally. A recent Dutch
study of 5,176 treatment cycles has externally validated IVFpredict but also showed that the
Templeton model had similar discrimination and calibration [18]. However, in addition to
having a relatively small sample size, that study only included couples with primary infertility
and excluded those who used donor eggs. The authors acknowledged that these limitations
were particularly likely to adversely affect the calibration of the IVFpredict model. Further-
more, the authors were only able to examine prediction of pregnancy, rather than live birth,
though a correction factor was used in an attempt to produce an estimated live birth rate.
The live birth rate from IVF has continued to increase since the development of IVFpredict
[20], and the mix of patients referred for IVF has changed [17]. Hence it is possible that it, as
well as the Templeton model, will need to be updated for accurate use in a new cohort [15]. In-
deed in the Dutch study, described above, both of the Templeton and IVFpredict models per-
formed better if adjustments were made for pregnancy/live birth success rate in each cohort
[18]. This raises the issue of whether, even with good prediction models that have been exter-
nally validated, their application in practice has to take account of success rates in the particular
population that the couple, their clinician and policy makers might consider they belong to.
Lastly, IVFpredict used broad female age categories, as during its development we were only
provided with data that allocated each treatment cycle to the woman’s age category publicly re-
ported by the Human Fertilisation and Embryology Authority (HFEA). This has been criticised
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as likely to result in marked over-fitting of our model [18]. As female age is the strongest pre-
dictor of live birth success [7], it is possible that female age alone could accurately predict suc-
cessful outcome, which would be a simple useful tool for all patients, clinicians and policy
makers.
The purpose of this study is to perform validation of the IVFpredict and Templeton predic-
tion models on a new UK cohort of IVF cycles. We aim to compare the predictive ability of the
two models and to examine how much each prediction model requires updating in a new sam-
ple where success rates vary from those in the cohort used to originally develop the model. We
also aim to quantify the value, in terms of predictive ability, of including covariates other than
female age in the prediction models. In the validation sample used here we have female age in
years at each cycle, and we also explore whether the predictive ability of IVFpredict is improved
by using female age as a continuous variable. Since the quantity and quality of validation stud-
ies has been criticised [21], we aim to make use of a large validation sample size and perform
all of the validation measures recommended in recent literature [21–23].
Materials and Methods
Ethics statement
The HFEA provided ethical approval for this study. All data were analyzed anonymously.
Data
The HFEA has a statutory duty to collect and record information about every assisted concep-
tion treatment in the UK. By law, every treatment centre must report certain couple character-
istics, treatment details and outcomes for every initiated IVF cycle. The HFEA provided a
database of all IVF cycles in the UK in the period 2003–2010. A cycle of IVF was defined as an
initiated ovarian stimulation or planned fresh or frozen embryo transfer. Since IVFpredict was
built using data from 2003–2007, we restricted the validation sample used here to cycles occur-
ring in 2008–2010. Data on live births for cycles initiated in 2011 onwards were not completely
available. We used the same exclusion criteria as our previous study where we developed IVF-
predict and compared it with the Templeton model, excluding treatments that are not IVF (i.e.
involve donor insemination or gamete/zygote intra-fallopian transfer), involve the storage or
donation of eggs, or use frozen embryo transfer [12]. IVFpredict cannot give a prediction for
women aged more than 50 years, so cycles from these women were excluded along with cycles
for which data on the duration of infertility were missing.
Prediction models
The Templeton and IVFpredict models use a linear predictor that differs with patient and cycle
characteristics. This is converted into the predicted probability of a live birth using the logistic
transformation. Equivalently, the linear predictor equals the log odds of a live birth.
IVFpredict
The variables used by IVFpredict are: female age (categorized as 18–34, 35–37, 38–39, 40–42,
43–44 and 45–50 years), duration of infertility (less than 1, 1–3, 4–6, 7–9, 10–12 and more
than 12 years attempting to conceive), cause of infertility (tubal, ovulatory, endometriosis, cer-
vical, male or combined), number of previous IVF cycles and number of previous unsuccessful
IVF cycles, pregnancy history, type of ovulation induction, whether ICSI was used, and wheth-
er donor or the patient’s own eggs were used [12]. Gonadatropins are now recognized as the
optimal agent for induction of multifollicular growth for IVF [24]. In our validation sample the
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agent used was not recorded for 128,438 cycles (98.1%), but it was recorded as gonadatropins
in 2,511 cycles (99.6%) where it was reported. We therefore assumed that all cycles used gona-
datropins and gave the IVFpredict linear effect attributed to this to all cycles. The interaction
terms included in IVFpredict: between female age and duration, female age and egg source,
ICSI and cause of infertility, and ICSI and number of previous IVF cycles, were included here.
Templeton model
The Templeton model uses female age (considered as a continuous variable with its effect on
the log odds represented by a cubic curve), duration of infertility (less than 4, 4–6, 7–12 and
more than 12 years), number of previously unsuccessful IVF cycles, pregnancy history, and
tubal cause of infertility [7]. The original Templeton model does not include any interactions.
Female age-alone models
We wished to compare both the Templeton and IVFpredict models with a model that predicts
live birth outcome using female age alone. However, there was no clear candidate for such a
model in the literature, and it would not be appropriate to develop one using the validation
data as its performance would be biased in the validation data. Instead, we considered a model
in which the predicted probability of live birth decreased as female age increased. The exact
shape of the relationship between female age and predicted probability of live birth does not af-
fect the discriminatory power of this model, provided we assume this monotonic relationship.
We also considered a model that used the HFEA age categories to inform prediction, again
with decreasing live birth rate with increasing female age, in order to measure the reduction in
discriminatory power associated with using female age as a categorical rather than continuous
variable.
Statistical methods
We used several methods, recommended in recent reviews [21–23], to assess the validity of
both models and compare their performance in the validation sample. These methods may be
thought of as assessing discriminatory power, calibration, or a combination of these two prop-
erties of a prediction model. Discriminatory power refers to the ability of a prediction model to
discriminate between successful and unsuccessful outcomes. This was assessed using the area
under the receiver-operator curve (AUROC). In this context the AUROC is the probability
that a model will predict a better prognosis for a randomly-selected cycle that resulted in a live
birth than a randomly-selected cycle that did not result in a live birth. We compared the
AUROC of IVFpredict with the reported AUROC and confidence intervals (CIs) in the IVF-
predict development sample [12], using a Wald test, assuming independence between the de-
velopment and validation samples.
Calibration refers to the similarity between the observed and predicted live birth rate in
groups of cycles. We assessed general calibration using calibration plots, which average the ob-
served and predicted live birth rate over deciles of the linear predictor. In a calibration plot, the
observed live birth rate is plotted against predicted live birth rate, and perfect calibration is in-
dicated by a straight line, with a gradient of one, through the origin. We used linear regression
to estimate the intercept and slope of the closest-fitting straight line to the points on the cali-
bration plot, and assessed departures from perfect calibration using the Hosmer-Lemeshow
test [25 p147–156]. We also assessed calibration over patient and cycle characteristics by com-
paring the observed and predicted live birth rates by female age, egg source, duration of infertil-
ity, number of previously unsuccessful IVF cycles, previous live birth from IVF, cause of
infertility, and use of ICSI. Here, departures from perfect calibration were assessed with
Validation and Calibration of IVFpredict
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Pearson’s chi-squared test and p-values were considered against a Bonferroni-corrected thresh-
old that ensured the family-wise error rate for all tests of calibration over patient and cycle
characteristics was not greater than 5%.
The Brier score is a combination of the discriminatory power and calibration of a prediction
model [26 p284–287]. We calculated modified Brier scores, being the Euclidean distance be-
tween observed and predicted live birth rates over deciles of the linear predictor, and scaled
them by dividing by the sample variance of the observed live birth rate. The scaled modified
Brier scores can be decomposed into measures of reliability and resolution. The reliability is a
goodness-of-fit statistic and is related to the Hosmer-Lemeshow test for calibration. The reso-
lution measures the range of probabilities that the prediction model can handle, with a higher
value indicating that the model can predict over a larger range of probabilities, which given
IVF treatment is now used in couples ranging from complete infertility to marginally reduced
fertility (or even normal fertility), is desirable [20]. When the overall observed and predicted
live birth rates are equal, as in the updated models, the scaled Brier score is the proportion of
variation in observed live birth rates not explained by the prediction model.
It has been suggested that prediction models can be compared by evaluating how many pa-
tients are correctly reclassified from one treatment recommendation to another [23]. Since
both the IVFpredict and Templeton models (and other models for predicting successful preg-
nancy/live birth outcome) do not give thresholds of prognosis or treatment recommendations,
only the predicted probability of live birth, it is not possible to compare them in this way. How-
ever it is possible to assess, for each cycle, which prediction model gave a prognosis closer to
the truth. We did this by cross-tabulating the number of cycles resulting in live births against
the prediction model that gave a higher probability of success to that cycle. We also calculated
a continuous version of the net reclassification index [27], which was calculated as twice the
proportion of live births given a higher prognosis by IVFpredict minus twice the proportion of
cycles not resulting in a live birth given a higher prognosis by IVFpredict.
For each of the IVFpredict and Templeton models we assessed two different predictions.
The first was calculated using the original values for the linear predictors. The second predic-
tion was updated for the validation sample by adding a constant term to the linear predictor,
calculated numerically by trial-and-improvement to ensure that the average observed and pre-
dicted live birth rates in the whole sample were equal. The simpler method of adjusting the lin-
ear predictor by adding the difference between the observed and predicted log odds of live
birth [28], would not achieve this, nor would adding the difference between the observed log
odds of live birth in the validation sample compared with the development sample, as was
done in the Dutch study [18]. A more complicated method is to refit the prediction model to
the validation sample by re-running the logistic regression [15,17], or to use a calibration plot
to find an adjusted prediction (vertical value) corresponding to each predicted prognosis (hori-
zontal value). A drawback of these methods is that they cause the validation sample to become
a new development sample, hence the refit model requires further validation, and therefore we
did not use these methods. Updating the models, using any of the methods above, would affect
their calibration but not their discriminatory power.
All statistical analyses were performed using Stata version 12 (StataCorp LP).
Results
There were 132,796 eligible IVF cycles that took place in the UK between 2008 and 2010. It was
not possible to calculate a predicted probability of live birth for 1.4% of these cycles, due to
missing information on duration of infertility or patient age greater than 50 years. There were
a remaining 130,960 cycles available for validation; details of the formation of the validation
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sample are given in Fig. 1. Table 1 shows the characteristics of the treatment cycles in this
study. Over half (51.7%) of cycles involved ICSI, and the proportion of cycles involving donor
eggs increased with female age. There were 33,553 live births, giving a successful live birth rate
of 25.6% per cycle in this cohort.
Discrimination
Table 2 shows the AUROC for the IVFpredict and Templeton models. Despite strong statistical
evidence for a difference in discrimination, with IVFpredict performing better than Templeton,
the AUROC values were similar for the two models, with both showing good discrimination.
IVFpredict had slightly poorer discrimination in this validation cohort than in the original co-
hort, and both models had better discrimination than a model based on female age alone as a
continuous variable. The categorisation of female age resulted in a decrease in AUROC of
0.004, which was 0.7% of the AUROC of IVFpredict, suggesting that there would be a very
small increase in AUROC if IVFpredict were to be redesigned to use female age as a continuous
variable.
Calibration
Fig. 2 shows calibration plots for the IVFpredict and Templeton models, showing observed ver-
sus expected live birth rates per decile of the linear predictor of each model. Perfect calibration
is depicted by the reference line in Fig. 2, which has an intercept of 0 and a slope of 1. In con-
trast, the IVFpredict calibration plot had an intercept of 0.040 (95% CI: 0.017–0.063) and slope
of 0.932 (95% CI: 0.839–1.025), and the Templeton model calibration plot had an intercept of
0.080 (95% CI: 0.044–0.117) and slope of 1.419 (95% CI: 1.149–1.690). Both models underesti-
mate the live birth rate—this is seen in Fig. 2 as the calibration curves lie above the reference
Fig 1. Inclusion/exclusion criteria and formation of the validation sample.
doi:10.1371/journal.pone.0121357.g001
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line—indicating that observed live birth rates were above those predicted. This is particularly
marked in the Templeton Model. The actual differences between observed and predicted live
birth rates are given in S1 Table.
Effect on calibration of updating the prediction models
Both models required updating to ensure that the predicted live birth rate was, on average,
equal to the observed live birth rate in the validation sample. IVFpredict was updated by adding
0.1396 to the linear predictor, thus increasing the predicted odds of live birth by a factor of
Table 1. Characteristics of patients and treatment in the validation sample, consisting of 130,960 IVF cycles.
Characteristic Number in sample Percentage of sample Percentage using donor eggs
Live births 33,553 25.6%
Patient age at treatment (years)
18–34 53,556 40.9% 1.0%
35–37 31,240 23.4% 1.6%
38–39 21,348 16.3% 2.2%
40–42 18,143 13.9% 4.8%
43–44 4,688 3.6% 14.0%
45–50 1,985 1.5% 49.0%
Duration of infertility (years)
0 3,125 2.4%
1–3 59,996 45.8%
4–6 44,400 33.9%
7–9 14,485 11.1%
10–12 5,560 4.3%
13- 3,394 2.6%
Previous live birth
Yes 23,444 17.9%
No 107,516 82.1%
Previous unsuccessful IVF cycles
0 83,838 64.0%
1 25,051 19.1%
2 11,862 9.1%
3- 10,209 7.8%
Treatment type
IVF 63,245 48.3%
IVF plus ICSI 67,715 51.7%
Source of egg
Patient 126,962 97.0%
Donor 3,998 3.0%
Cause of infertility
Unexplained 45,928 35.1%
Tubal only 15,244 11.6%
Ovulatory only 8,526 6.5%
Endometriosis only 5,164 3.9%
Cervical only 5 0.0%
Male cause only 43,663 33.3%
Multiple causes 12,430 9.5%
doi:10.1371/journal.pone.0121357.t001
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1.15. The Templeton model required a greater change: adding 0.9269 to the linear predictor, in-
creasing the predicted odds of live birth by a factor of 2.53.
Calibration plots for both updated models are shown in Fig. 3 (S2 Table). Both models
showed a closer adherence to the reference line, although the Hosmer-Lemeshow test still
Table 2. Area under the receiver-operator curve for IVFpredict and Templeton models, and female
age alone, for predicting live birth from 130,960 IVF cycles.
AUROC (95% CI) Difference from row above
IVFpredict, development sample* 0.635 (0.630, 0.637)
IVFpredict 0.628 (0.625, 0.631) 0.006 (p = 0.019)
Templeton model 0.616 (0.613, 0.620) 0.012 (p < 0.001)
Continuous female age** 0.610 (0.606, 0.612) 0.007 (p < 0.001)
Categorical female age*** 0.604 (0.601, 0.608) 0.004 (p < 0.001)
* Based on 144,018 cycles occurring in the UK between 2003 and 2007 [12].
** Model predicting decreasing probability of live birth with increasing female age.
*** Model predicting decreasing probability of live birth with increasing female age categories (18–34, 35–
37, 38–39, 40–42, 43–44 and 45–50 years).
doi:10.1371/journal.pone.0121357.t002
Fig 2. Calibration plot for the IVFpredict and Templeton models. Based on 130,960 IVF cycles. Hosmer-
Lemeshow test statistics: p<0.001. Solid line, IVFpredict model; dashed line, Templeton model; dotted,
diagonal line, perfect prediction (reference).
doi:10.1371/journal.pone.0121357.g002
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showed strong statistical evidence of imperfect calibration in both models. As in the validation
models without updating, calibration was better for the IVFpredict than the Templeton model.
The IVFpredict calibration plot had a slope of 0.867 (95% CI: 0.789–0.946) whilst the Temple-
ton calibration plot had a slope of 0.804 (95% CI: 0.697–0.912). Slopes less than 1 demonstrate
that both updated models overestimated the live birth rate in couples with good prognosis, and
underestimated the live birth rate in couples with poor prognosis. Since both models have been
updated, the average observed and predicted live birth rates are equal, so the intercepts of the
calibration plots give no additional information about the calibration of each updated model.
Calibration by different couple characteristics
Table 3 shows the calibration of both updated models by couple characteristics. IVFpredict did
not show differential calibration with respect to cause of infertility and treatment type, whilst
the Templeton model showed differential calibration over all variables considered in Table 3.
Both models underestimated the live birth rate in patients using donor eggs, particularly in
women aged 38 years or older, but this was more marked in the updated Templeton model. In
women aged 45 years or older using donor eggs the predicted live birth rate from the Temple-
ton model was only 8% (95% CI: 7–9%) of the observed live birth rate, whereas from
Fig 3. Calibration plot for updated IVFpredict and Templetonmodels. Based on 130,960 IVF cycles.
Hosmer-Lemeshow test statistics: p<0.001. Solid line, updated IVFpredict model; dashed line, updated
Templeton model; dotted, diagonal line, perfect prediction (reference).
doi:10.1371/journal.pone.0121357.g003
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Table 3. Observed and predicted live birth rates from updated IVFpredict and Templetonmodels stratified by characteristics of patients and treat-
ment, in 130,960 IVF cycles.
IVFpredict Templeton
Observed live
birth rate
Predicted live birth
rate (SD)
Ratio predicted to
observed (95% CI)
Predicted live birth
rate (SD)
Ratio predicted to
observed (95% CI)
Female age (years) patient eggs
18–34 0.326 0.330 (0.060) 1.013 (1.000, 1.025) 0.327 (0.058) 1.004 (0.992, 1.016)
35–37 0.273 0.273 (0.056) 0.999 (0.980, 1.017) 0.272 (0.066) 0.996 (0.978, 1.014)
38–39 0.198 0.202 (0.047) 1.020 (0.992, 1.047) 0.210 (0.059) 1.062 (1.033, 1.091)
40–42 0.129 0.123 (0.033) 0.949 (0.913, 0.986) 0.148 (0.051) 1.140 (1.096, 1.184)
43–44 0.050 0.045 (0.015) 0.907 (0.785, 1.029) 0.079 (0.029) 1.574 (1.362, 1.785)
45–50 0.020 0.022 (0.014) 1.120 (0.631, 1.609) 0.036 (0.016) 1.827 (1.031, 2.623)
p = 0.02 p < 0.001
Female age (years) donor eggs
18–34 0.301 0.317 (0.067) 1.054 (0.917, 1.191) 0.322 (0.064) 1.070 (0.931, 1.209)
35–37 0.324 0.345 (0.072) 1.064 (0.930, 1.199) 0.257 (0.069) 0.792 (0.692, 0.893)
38–39 0.328 0.236 (0.055) 0.721 (0.627, 0.815) 0.187 (0.052) 0.569 (0.494, 0.645)
40–42 0.328 0.300 (0.068) 0.914 (0.826, 1.002) 0.123 (0.045) 0.376 (0.339, 0.412)
43–44 0.344 0.253 (0.080) 0.736 (0.656, 0.815) 0.068 (0.027) 0.197 (0.175, 0.219)
45–50 0.327 0.276 (0.117) 0.844 (0.766, 0.921) 0.026 (0.017) 0.079 (0.071, 0.086)
p < 0.001 p < 0.001
Source of egg
Patient 0.254 0.255 (0.099) 1.005 (0.996, 1.014) 0.260 (0.094) 1.023 (1.013, 1.032)
Donor 0.326 0.287 (0.090) 0.879 (0.839, 0.919) 0.141 (0.112) 0.433 (0.411, 0.455)
p < 0.001 p < 0.001
Duration of infertility (years)
0 0.267 0.330 (0.118) 1.237 (1.167, 1.308) 0.264 (0.105) 0.988 (0.932, 1.044)
1–3 0.269 0.271 (0.103) 1.007 (0.994, 1.020) 0.281 (0.093) 1.044 (1.030, 1.057)
4–6 0.259 0.249 (0.089) 0.962 (0.947, 0.977) 0.237 (0.088) 0.918 (0.904, 0.932)
7–9 0.229 0.236 (0.093) 1.032 (1.001, 1.062) 0.242 (0.104) 1.060 (1.028, 1.091)
10–12 0.212 0.211 (0.086) 0.998 (0.949, 1.048) 0.230 (0.104) 1.088 (1.033, 1.143)
13- 0.181 0.191 (0.090) 1.055 (0.981, 1.130) 0.164 (0.092) 0.910 (0.845, 0.975)
p < 0.001 p < 0.001
Previous unsuccessful IVF cycles
0 0.275 0.289 (0.094) 1.050 (1.039, 1.061) 0.280 (0.096) 1.017 (1.006, 1.028)
1 0.224 0.205 (0.079) 0.915 (0.895, 0.936) 0.232 (0.083) 1.037 (1.014, 1.061)
2 0.227 0.196 (0.075) 0.861 (0.833, 0.889) 0.209 (0.080) 0.920 (0.890, 0.951)
3+ 0.211 0.181 (0.080) 0.859 (0.827, 0.891) 0.173 (0.077) 0.821 (0.791, 0.852)
p < 0.001 p < 0.001
Previous live birth by IVF
No 0.253 0.251 (0.096) 0.993 (0.983, 1.003) 0.246 (0.086) 0.975 (0.965, 0.985)
Yes 0.272 0.280 (0.111) 1.028 (1.007, 1.049) 0.301 (0.127) 1.105 (1.082, 1.128)
p = 0.01 p < 0.001
Treatment type
IVF 0.234 0.234 (0.091) 1.001 (0.987, 1.015) 0.249 (0.102) 1.065 (1.050, 1.080)
ICSI 0.277 0.277 (0.095) 0.999 (0.987, 1.011) 0.263 (0.098) 0.949 (0.938, 0.960)
p = 0.77 p < 0.001
Cause of infertility
Unexplained 0.242 0.244 (0.102) 1.007 (0.991, 1.023) 0.237 (0.098) 0.980 (0.964, 0.995)
(Continued)
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IVFpredict it was 84% (95% CI: 77–92%). The Templeton model overestimated the live birth
rate in women aged 38 years or older using their own eggs and women with a tubal cause of
infertility, whilst underestimating the live birth rate in women who had not previously had a
live birth from IVF, and couples using ICSI.
Overall performance
Brier scores for all four models (IVFpredict and Templeton, original and updated) are shown
in Table 4. The original and updated IVFpredict models had smaller Brier scores than the Tem-
pleton model, indicating better predictive accuracy. The updated models had better reliability
than the original models, with IVFpredict having the best reliability. The IVFpredict models
also had higher resolution.
The rates in Table 5 show that, before updating, the Templeton model gives a lower proba-
bility of live birth than IVFpredict in 128,615 cycles (98.2%), as the Templeton model severely
underestimates the probability of live birth. Thus the Templeton model gave a more accurate
prognosis in cycles that did not result in a live birth and IVFpredict gave a more accurate prog-
nosis in the fewer cycles that resulted in a live birth. This comparison is much more meaningful
after updating both models. After updating, most women who had a live birth were given a
higher probability of live birth by IVFpredict than the Templeton model, and most women
who did not have a live birth were given a lower probability of live birth by IVFpredict. I.e.,
after updating, IVFpredict performed better than the Templeton model in terms of correctly
Table 3. (Continued)
IVFpredict Templeton
Observed live
birth rate
Predicted live birth
rate (SD)
Ratio predicted to
observed (95% CI)
Predicted live birth
rate (SD)
Ratio predicted to
observed (95% CI)
Tubal only 0.237 0.233 (0.085) 0.982 (0.955, 1.010) 0.255 (0.093) 1.074 (1.044, 1.104)
Ovulatory only 0.281 0.267 (0.093) 0.950 (0.918, 0.982) 0.266 (0.098) 0.949 (0.917, 0.981)
Endometriosis
only
0.253 0.253 (0.085) 0.998 (0.952, 1.043) 0.261 (0.086) 1.029 (0.982, 1.077)
Male cause only 0.271 0.274 (0.102) 1.011 (0.995, 1.026) 0.271 (0.097) 1.002 (0.987, 1.017)
Multiple causes 0.264 0.264 (0.094) 0.997 (0.968, 1.026) 0.266 (0.092) 1.006 (0.977, 1.035)
p = 0.09 p < 0.001
P-values are for differences between observed and predicted number of live births, and those smaller than the threshold for a family-wise error rate of 5%
are highlighted.
* Not including 5 cycles where cervical cause of infertility only, for which meaningful conﬁdence intervals cannot be calculated.
doi:10.1371/journal.pone.0121357.t003
Table 4. Brier scores and decomposition for IVFpredict and Templetonmodels, from 130,960 IVF cycles.
Scaled modiﬁed (Sanders) Brier score Scaled reliability (in-the-small) Scaled uncertainty
Templeton model
Original 1.065 0.096 0.032
Updated 0.971 0.003 0.032
IVFpredict
Original 0.965 0.004 0.039
Updated 0.963 0.001 0.039
Scaled modiﬁed Brier score = 1 + Scaled reliability—Scaled uncertainty.
doi:10.1371/journal.pone.0121357.t004
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predicting both having a live birth and not having a live birth. The net reclassification index
was positive, favouring IVFpredict over the Templeton model, for both the original and up-
dated models, being considerably higher for the updated models.
Discussion
In this study we have shown that IVFpredict externally validates and has good discrimination
and calibration in a large independent cohort. We have further shown that it has better dis-
crimination and calibration than the Templeton model for accurately predicting live birth.
This is the first time that IVFpredict has been validated for live birth outcome on a different
sample from that used for its development. The observed lower discrimination in comparison
to the original development sample is to be expected [21,29], but the magnitude of the differ-
ence is tiny (mean difference of 0.01) and the observed AUROC of 0.628 in this validation sam-
ple can be thought of as excellent discriminative performance, as it is higher than the supposed
maximum of 0.62 expected for a prediction model of IVF success [23]. Female age is the most
important predictor of live birth from IVF [30], and IVFpredict has the drawback that it con-
siders age in categories rather than a continuous measure. However, we demonstrated that
IVFpredict has better discriminatory power than any model based only on a monotone trans-
formation of female age, showing that the additional predictors used by IVFpredict give addi-
tional discriminatory power. As this was a validation study, it was not appropriate to
investigate how prediction models could be improved by the inclusion of additional variables.
The overall better performance, in terms of discrimination and calibration, of IVFpredict in
comparison with the Templeton model in this study, as in our original development cohort, is
in contrast to the conclusions of a recent Dutch study that reported similar discrimination and
calibration of the two models [18]. However, the differences between AUROC and calibration
for the two models in that study were minimal and, as discussed in the introduction, the Dutch
study was small, included only treatment cycles in couples with primary infertility, could not
include information on ICSI or whether women used their own or donor eggs and had preg-
nancy (rather than live birth) as the measured outcome. Our finding, that the Templeton
model underestimated the live birth rate by up to 17% in the current study, is consistent with
other studies that have previously demonstrated that the Templeton model was particularly
poorly calibrated when applied to contemporary cohorts [15,17]. The likely explanation for
this is the increase in the use and success of IVF in the two decades since the Templeton model
was originally developed. However, IVFpredict had better calibration even after both models
were updated to take account of the live birth rate in the contemporary UK cohort used here.
This is likely to be because the Templeton model does not consider ICSI and donor eggs as in-
formative predictors of prognosis and therefore incorrectly estimates, sometimes extremely,
the probability of live birth in cycles using these treatment methods.
Our preferred method of updating the prediction models to account for the differences in
IVF success in different populations caused the predicted live birth rate to equal the observed
live birth rate in the whole validation sample, therefore removing the systematic underestima-
tion exhibited by both models. The updated IVFpredict model had a calibration plot slope clos-
er to the target value than that of the Templeton model, and a better reliability in the Brier
score decomposition. Furthermore, the updated Templeton model overestimated the probabili-
ty of live birth in older women using their own eggs and women with a tubal cause of infertility,
and underestimated the probability of live birth from cycles using ICSI and women who had
not had a previous live birth from IVF. Both updated models underestimated the probability of
live birth in cycles using donor eggs, but this was more marked in the updated Templeton
model. The updated IVFpredict model had a smaller Brier score, indicating a better overall
Validation and Calibration of IVFpredict
PLOS ONE | DOI:10.1371/journal.pone.0121357 April 8, 2015 12 / 15
calibration, and in particular showed greater resolution in the Brier score decomposition. This
shows that IVFpredict has the desirable property of covering a greater range of probabilities
than the Templeton model [23], indicating that it carries more predictive prognostic informa-
tion [31]. Consistent with this, the updated IVFpredict model provided a more accurate prog-
nosis than the updated Templeton model for the majority (52.5%) of the cycles in the
validation sample.
Our results suggest that, whichever model is chosen for use in clinical practice, it should be
updated or recalibrated before it is used to inform patients of their prognosis. This validation
study has shown the potential for extremely misleading predictions if a poorly calibrated, out
of date model is used. Ideally recalibration should take place on a per-centre basis due to the
amount of variation in the live birth rate between treatment centres [15,30,32]. The simplest
method of recalibration would involve a treatment centre retrospectively applying a prediction
model to their recorded cycles, and calculating how much to add or subtract from the linear
predictor to ensure that the average predicted live birth rate equals the observed live birth rate
at that centre. Larger centres could create calibration plots, as in Fig. 2, and use this as described
above to convert a probability given by the prediction model for certain patient characteristics
into a centre-specific probability for that patient. Unfortunately the HFEA dataset used here
did not contain centre details for each cycle, so we could not assess the efficacy of per-
centre recalibration.
This study benefits from a large validation sample that is highly representative of the target
population. It should be noted that, since both the IVFpredict and Templeton models were de-
veloped using UK HFEA data, we were only able to perform temporal validation [30]. External
validation of the ability of IVFpredict to predict live birth rate in couples with both primary
and secondary infertility in a large non-UK population is required to assess its global applica-
bility. Neither IVFpredict nor the Templeton model consider live birth from frozen embryo re-
placements, hence both models may be disadvantaged given the likelihood of increased use of
frozen embryo replacements. No prediction models for live birth after IVF have yet reached
the impact analysis stage and external validation is an essential step towards this [1]. In conclu-
sion, this validation study indicates that IVFpredict has superior discrimination and calibration
to the Templeton model for informing patients and clinicians in the UK of the prognosis of
live birth following IVF. IVFpredict exhibits improved calibration after updating, and recali-
bration can be applied on a per-centre basis in clinical practice.
Table 5. Net reclassification index for IVFpredict compared with the Templetonmodel.
Original
Prognosis No live birth Live birth
IVFpredict higher than Templeton 95,304 (97.8%) 33,311 (99.3%)
Templeton higher than IVFpredict 2,103 (2.2%) 242 (0.7%)
Net reclassiﬁcation index 2.88% from Templeton to IVFpredict
Updated*
Prognosis No live birth Live birth
IVFpredict higher than Templeton 46,750 (48.0%) 18,143 (54.1%)
Templeton higher than IVFpredict 50,654 (52.0%) 15,410 (45.9%)
Net reclassiﬁcation index 12.2% from Templeton to IVFpredict
* Not including 3 cycles with equal prognosis in the updated IVFpredict and Templeton models.
doi:10.1371/journal.pone.0121357.t005
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